

## About Us

Founded in 2017, Sonic Incytes Medical Corp. is a privately held health technology company headquartered in Vancouver, Canada. Our lead product, Velacur™, is set to enter the US market in early 2021.

At Sonic Incytes, we believe in creating accessible and affordable solutions for healthcare providers with health insights they can count on to improve patient care. Nowhere in medicine is this more applicable than the silent health crisis of chronic liver disease.

Affecting 100 million Americans by 2030, and millions more around the world, chronic liver disease is an emerging global health crisis.

Healthcare practitioners are not well equipped to manage this disease because existing diagnostic tools are either expensive, inefficient, inaccessible or inaccurate.

Recognizing the rise of chronic liver disease, we've made it our mission to reduce the disease by enabling routine assessment and management of liver health with our breakthrough, point of care ultrasound solution, Velacur™.

Velacur™ is redefining the standard of care in quantifying chronic liver disease with diagnostic accuracy comparable to MRI.

## Key Events

**2017**

Company Founded

**2018**

Feasibility Study Completed

**2019**

Pivotal Study Initial Data Release

**2020**\$3.5M Seed Raise  
FDA Clearance  
Pivotal Study Comparison to MRI Data Release**2021**

Velacur™ Commercial Launch

## Leadership Team

**George Aliphtiras**  
CEO

Former CEO and Founder, BioMers

**Dr. Tim Salcudean**  
Co-founder / CTO

University of British Columbia Professor, Lazlo Chair in ultrasound and robotics

**Dr. Robert Rohling**  
Co-founder / CSO

University of British Columbia Professor, ICICS Director in ultrasound and AI

**Joseph Lee**  
CFO

Former CFO, TerraMera

**Brian Stachniak**  
Director of Product

Former Manager, McKesson Imaging

**Jeffrey Haar**  
Director of Sales

Former National Sales Manager, Diversatek Health and Echosens (FibroScan)

## Board of Directors

**Dr. Kenneth Moritsugu**

Former US Deputy Surgeon General, Rear Admiral US Public Health Service

**Dr. Chris Nguan**

Urologist, Head Kidney Transplant, Vancouver Coastal Health

**Daniel Cordingley**

Former CEO and Founder, Teradici

**Natalie Dakers**


Former CEO and Founder, Accel-Rx and CDRD



## Our Strategy

- Develop quantitative ultrasound for point-of-care applications
- Provide advanced diagnostic capabilities comparable to MRI elastography using handheld ultrasound
- Partner with leading clinical research institutions and industry in Canada, the US and internationally
- First commercial application: chronic liver disease, consisting of NAFLD/NASH, autoimmune, viral, and transplant
- Prioritized markets: North America, Asia and Europe
- Future clinical applications: various fibrotic diseases (liver, kidney, etc.) and cancer (liver, prostate, etc.) and other disorders

## Development Pipeline – Application Readiness



## Velacur™

Velacur™ is the first handheld 3D liver tissue assessment tool with diagnostic accuracy comparable to MRI, the current non-invasive gold standard. Our proprietary technology uses steady state waves, the same used by MRI elastography, to quantify liver disease, paving the way for a non-invasive, low-cost and scalable solution to assess and manage millions of patients.

Velacur™ consists of a handheld ultrasound and an activation pad. The patient lies on the activation pad, which creates steady state waves in the liver, and a 3D tissue sample is measured using the ultrasound probe.

The entire procedure takes about five minutes in a doctor's office, providing for a quick, safe and comfortable patient experience. Results are available immediately, and its portability allows physicians to integrate it into multiple practice settings with ease.

With minimal upfront investment, a potential new revenue stream for physicians, and a procedure simple enough to be delegated by the physician, Velacur™ offers a cost-effective solution and improved patient management for this burgeoning disease.

### US Fatty Liver Disease Market Quick Facts

Prevalence:

**1 in 3 Americans  
(100 Million)**

Healthcare Costs:

**\$103B / Annum**

Diagnostic Market Size:

**\$2B**